AstraZeneca CEO Pascal Soriot’s Pay Rises to £17.7m in 2024

In Brief

AstraZeneca CEO Pascal Soriot received a 6.4% pay increase, totaling £17.7m in 2024, according to company reports.

Key Facts

• Pascal Soriot is the chief executive of AstraZeneca, Britain’s largest pharmaceutical company
• According to AstraZeneca’s 2024 annual report, Soriot’s total remuneration was £17.7 million
• The report states his pay rose by 6.4% compared to the previous year
• Nearly £16 million of his pay came from bonuses and share awards, as detailed in the report
• The company’s report indicates he may receive a further pay increase in 2025, potentially making him the UK’s highest-paid CEO again

What Happened

AstraZeneca’s 2024 annual report showed that CEO Pascal Soriot received a 6.4% pay rise, bringing his total remuneration to £17.7 million. The report specifies that nearly £16 million of this amount was from bonuses and share awards. The company also noted the possibility of a further pay increase for Soriot in 2025.

Why It Matters

The information from AstraZeneca’s report provides insight into executive compensation within the pharmaceutical industry. The reported pay rise occurs alongside the company’s financial performance, as noted in the same report. This data contributes to ongoing public and industry discussions about executive pay levels.